0 items USD 0.00Search
Your search for "globaldata hemophilia b recombinant factor replacement therapy argentina drug forecast" gave back 1539284 results.
The global Medication for Hemophilia market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a...
Catalog:
GIR
March 2024
Price: USD 3,480.00
Haemophilia is a group of inherited genetic disorders which causes abnormal or exaggerated bleeding. It impairs the normal mechanism of blood...
Catalog:
MRRPB5
June 2023
Price: USD 4,900.00
Haemophilia is a group of inherited genetic disorders which causes abnormal or exaggerated bleeding. It impairs the normal mechanism of blood...
Catalog:
LPI
March 2023
Price: USD 3,660.00
Haemophilia is a group of inherited genetic disorders which causes abnormal or exaggerated bleeding. It impairs the normal mechanism of blood...
Catalog:
MRRPB5
February 2024
Price: USD 2,900.00
Haemophilia is a group of inherited genetic disorders which causes abnormal or exaggerated bleeding. It impairs the normal mechanism of blood...
Catalog:
MRRPB5
April 2023
Price: USD 2,900.00
Hemophilia B - Pipeline Review, H1 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B...
Catalog:
Global Markets Direct
March 2018
Price: USD 2,000.00
The global Medication for Hemophilia market size is expected to reach $ million by 2030, rising at a market growth of % CAGR during the forecast...
Catalog:
GIR
March 2024
Price: USD 4,480.00
A Pipeline Landscape Analysis and Comparative Assessment of Key Players: This report provides an update of recombinant coagulation factors used for...
Catalog:
La Merie Publishing
December 2014
Price: USD 2,680.00
The hemophilia treatment drugs market is experiencing entry of a large number of new drugs in the market. Few of them have already arrived and other...
Catalog:
MRRPB5
February 2023
Price: USD 2,900.00
The hemophilia treatment drugs market is experiencing entry of a large number of new drugs in the market. Few of them have already arrived and other...
Catalog:
LPI
February 2023
Price: USD 3,660.00
Novo Nordisk A/S - Strategy, SWOT and Corporate Finance Report Summary Novo Nordisk A/S - Strategy, SWOT and Corporate Finance Report, is a source of...
MarketLine
December 2022
Price: USD 175.00
Hemophilia is a hereditary genetic disorder which impairs body’s ability to control coagulation or blood clotting. In this disease, clotting factors...
Catalog:
MRRPB5
November 2023
Price: USD 3,350.00
Hemophilia is a hereditary genetic disorder which impairs body’s ability to control coagulation or blood clotting. In this disease, clotting factors...
Catalog:
GIR
January 2023
Price: USD 3,480.00
The global Recombinant Protein Drug R & D market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of...
Catalog:
MRRPB5
October 2023
Price: USD 2,900.00
ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in...
Catalog:
MRRPB5
October 2023
Price: USD 2,900.00
